Category Archives: U.S. Policy and Funding

Country’s effort toward historic HCV elimination goal highlights challenges

By on .

A small Eastern European country with limited resources and a high prevalence of hepatitis C, Georgia had factors in its favor in 2015, when it launched a historic effort to eliminate the virus. It had demonstrated both political will and technical capacities with an approach to universal access to health services that had led to […]

Treatment rationing, other structural barriers stand in the way of stopping spread of hepatitis C among people living with HIV, study finds

By on .

When provinces in Canada lifted restrictions pegging eligibility for treatment for hepatitis C with direct-acting antivirals to the stage of the disease — or range of liver damage — to make the medicines universally accessible, the numbers of people who accessed the treatment nearly doubled, a study reported in Clinical Infectious Diseases found. New initiation […]

Gilead hepatitis C drug price deal leaves global treatment access advocates underwhelmed

By on .

When the U.S. Food and Drug Administration approved sofosbuvir for the treatment of chronic hepatitis C in early December, it was a step that was “expected to dramatically improve outcomes for many patients,” as one report put it. But how many was a big question, as we noted here. While the drug shortens treatment for […]